We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 11.50 | 0.70% | 1,651.00 | 1,651.00 | 1,652.00 | 1,656.00 | 1,637.00 | 1,650.50 | 4,661,376 | 16:35:08 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.80 | 68.01B |
From Apr 2022 to Apr 2024
By Joshua Kirby
Sanofi SA said Friday that its coronavirus booster vaccine, developed alongside Britain's GSK PLC, has produced successful results against the Omicron variant of the coronavirus in an efficacy study.
The French biopharmaceutical company said its vaccine candidate showed efficacy against the virus in an environment of high Omicron variation. It showed 72% efficacy against the strain in adult, as well as a favorable safety and tolerability profile, the company said.
Along with positive data from two previous trials, the results will be submitted to regulatory authorities for approval, Sanofi said.
The results "indicate the potential of Sanofi-GSK's next-generation Beta-based booster to be a relevant response to public health needs," the company said.
Write to Joshua Kirby at joshua.kirby@wsj.com; @joshualeokirby
(END) Dow Jones Newswires
June 24, 2022 02:06 ET (06:06 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
